Protein Sciences Corporation reports topline data showing that Flublok® Quadrivalent – the quadrivalent version of FDA-approved trivalent Flublok® influenza vaccine – outperformed a traditional influenza vaccine last season and was better at preventing the flu.

“This study points out the advantages of using modern technology to overcome problems with traditional influenza vaccine manufacturing,” said Manon Cox, President and CEO of Protein Sciences. “Ten years ago we had the first evidence in clinical trial PSC01 that more antigen was beneficial even for healthy adults.  Today with support from the Biomedical Advanced Research and Development Authority we were able to show statistically significant better performance than traditional egg-produced vaccines” … more

Earlier this month, Protein Sciences reported that the FDA is granting “exclusivity” to Flublok® for a period of 12 years. “The FDA’s designation prevents a generic product maker from capitalizing on the hard work of our team,” Dr. Cox said … more